Ublituximab significantly improves patient-reported outcomes: results from the phase 4 observational study ENABLE By Sheena Cruz / 05/26/2026
Evaluation of Ublituximab Infusion Tolerability: Analysis of Data Following the ULTIMATE Phase 3 Studies By Sheena Cruz / 05/26/2026
Evaluating the Presence and Concentration of BRIUMVI® (ublituximab-xiiy) in Breastmilk (PROVIDE): An Interim Report By Sheena Cruz / 05/26/2026
Real-World Transition to Ublituximab From Prior Anti-CD20 Treatment in the Phase 4 ENABLE Study By Sheena Cruz / 05/26/2026
Safety and Tolerability of 30-minute Ublituximab Infusions: Updates from the ENHANCE Study By admin / 05/29/2025
Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR) By admin / 05/29/2025
No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long term ublituximab (UBL) treatment in patients with Relapsing Multiple Sclerosis (RMS) By admin / 05/29/2025
BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated with BRIUMVI (ublituximab-xiiy) By admin / 05/30/2024
A Post-Marketing Study Evaluating the Presence and Concentration of BRIUMVI®(ublituximab-xiiy) in Breastmilk (PROVIDE) By admin / 05/30/2024
Ublituximab Is Associated with Significant Improvement in Fatigue: Results from Ultimate I and II By admin / 06/01/2023
